Reducing Tobacco Harm: Finding the Best Route for Africa

Aug.15.2022
Reducing Tobacco Harm: Finding the Best Route for Africa
Reducing tobacco harm is a public health strategy that advocates for harm reduction products as a practical approach to lower smoking rates.

The entire world agrees that smoking rates need to be decreased. Whether it's the ubiquitous cigarette or local cigars and hookahs known as shisha in Nigeria, all stakeholders want to reduce smoking rates, and in fact, keep reducing them. While cigarettes have always received the most attention, people are now beginning to recognize the dangers of shisha, especially as it becomes increasingly popular among young people.


However, the means to achieve the expected decrease in smoking rates continue to cause debate among various parties. The popular African saying, "there are different paths to reach the same destination" is a subtle way our ancestors chose to remind us that the destination is the ultimate goal. Naturally, as long as the expected destination or established objective is reached, everything is fair and great, without any mistakes made along the way.


In fact, this motto has never been more important than in the process of reducing smoking rates in Africa today. While the debate about the path to this destination continues, prohibitionists – those who believe that only complete abstinence from smoking can achieve a decrease in smoking rates – continue to denigrate advocates for harm reduction, while also denying the success of harm reduction plans.


The photo, taken by Haim Charbit on Unsplash, represents a public health strategy called tobacco harm reduction (THR), which aims to reduce personal and wider societal health risks associated with combustible tobacco products. This approach is based on the understanding that most of the harm related to combustible tobacco is caused by the chemical mixture released when tobacco is burned (smoked) and then inhaled. However, if you remove the smoking/burning element, the risk of consuming tobacco is significantly reduced.


THR advocates believe that many adult smokers who wish to quit smoking often struggle or cannot quit, while others wish to continue to enjoy nicotine without harmful effects. Therefore, these smokers should switch to alternative products that release nicotine without burning tobacco. The word "switching" is an effective term for THR advocates, who prioritize the freedom to switch and the availability of alternative options. Providing information on alternative or reduced-risk products is a key driver of effective THR strategies for adult consumers to make informed choices.


Recently, advocates of tobacco harm reduction (THR) have been promoting their cause in Africa by explaining the science behind the concept and citing successful records from countries that have accepted the ideology of reducing tobacco harm. It is worth noting that THR advocates still agree that quitting smoking is the best choice and frequently emphasize this fact. However, they have chosen a pragmatic approach because they understand that both quitting smoking and switching will achieve the goal of reducing smoking rates. The position of THR advocates is supported by scientific evidence from more developed economies, which recognizes that adopting and effectively implementing tobacco harm reduction strategies can significantly reduce smoking rates. For example, the United Kingdom has recognized the effectiveness of reducing tobacco harm or substituting tobacco products in lowering smoking rates. The National Institute for Health and Care Excellence (NICE), which publishes evidence-based guidelines for the most effective methods of disease prevention, diagnosis, and treatment, has also released guidelines for tobacco harm reduction. The guidelines acknowledge that quitting smoking is always the best choice for smokers, but they support the use of licensed nicotine-containing products (NCPs) to help smokers who are currently unable to quit transition to less harmful options.


The Food and Drug Administration (FDA) of the United States of America (USA) has begun to classify alternative products as "reduced-risk tobacco products". This is a clear indication that the country is relying on scientific and verified evidence to provide guidance on reducing tobacco harm.


According to reports, Japan's smoking rate has decreased by 34% primarily due to the introduction of alternative products that give citizens the opportunity to switch to lower-risk options rather than outright quitting. This was detailed in a report by renowned consultancy firm Frost & Sullivan in December 2020, which also emphasized the importance of establishing effective regulation.


In Canada, the government has released a scientifically-supported statement through the Canadian Ministry of Health, stating that "completely replacing smoking with e-cigarettes will reduce your exposure to harmful chemicals" and "e-cigarette products and e-cigarettes release nicotine in a smaller way than smoking." Others are advising adult smokers to stay away from combustible tobacco products. The Canadian Public Health Association also recognizes the efficacy of alternative products and has released statements since 2018 acknowledging that the risks associated with alternative nicotine delivery products are lower than combustible tobacco.


New Zealand's Ministry of Health launched a website called Vaping Facts in 2019 with the aim of educating citizens about the realities of using e-cigarettes as a smoking cessation tool. The website encourages smokers to consider e-cigarettes as a means of quitting smoking and widely disseminates content indicating that the risks associated with vaping are lower than with smoking. This is another clear example of a country using a scientific and fact-based approach to reduce the harm caused by tobacco.


African countries need to conduct independent evaluations of each potential pathway towards reducing smoking rates. Their health departments and other health organizations, including academic members, must commission independent research focused not only on reducing tobacco harm but also examining the numerous public health issues affecting their citizens. This will aid in determining the best policies and regulatory frameworks to effectively promote smoking cessation and reduce tobacco harm simultaneously.


Statement


This article is compiled from third-party information and is intended for industry professionals for communication and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the content. The translation of this article is only for industry exchange and research purposes.


Due to limitations in the skill level of the translator, the translation may not accurately reflect the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government's positions and statements regarding domestic issues, as well as those concerning Hong Kong, Macau, Taiwan, and international relationships.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Philip Morris Japan (PMJ) launched TEREA Black Mint Pearl on October 15, 2026, introducing the first capsule-equipped heated tobacco stick in the TEREA Black range for IQOS ILUMA devices. The product combines a strong menthol profile with a crushable mint capsule and is priced at ¥640 per 20-stick pack, including tax. Sales began at four IQOS stores and selected retail partners on October 15, with distribution expanding to convenience stores and other tobacco retailers nationwide from October 19. The launch brings Japan's TEREA portfolio to 28 variants, including 21 menthol-related products, or 75% of the range.
product
Oct.16 by 2Firsts Perspectives
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Four CrossBar 20K disposable e-cigarettes appeared on Pennsylvania's 163-entry ENDS directory ahead of enforcement beginning October 19, 2026. The devices feature 13mL e-liquid reservoirs, 50mg/mL nicotine, 2,000mAh batteries and 0.9Ω mesh coils, with advertised puff counts of up to 20,000. CrossBar was the only modern high-puff disposable series among the directory's 15 disposable entries. Its packaging emphasizes New York design and Japanese-origin flavoring, while historical CrossBar records identify a registered U.S. tobacco manufacturing-related establishment. The link between the newer 13mL devices and earlier 1.3mL PMTA filings remains unconfirmed.
product
Oct.26
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Philip Morris Korea launched TEREA Limona Pearl in South Korea on August 31, 2026, expanding the TEREA Fresh Blend capsule tobacco stick lineup from four variants to five. Designed for the IQOS ILUMA series, the new stick combines a capsule with what the company calls a Fresh Filter. Philip Morris Korea describes the product as offering an aromatic, refreshing flavor profile with a cooling sensation, with an additional fresh note released when the capsule is crushed. The recommended retail price is KRW 4,800 per pack, with sales through IQOS stores and convenience stores nationwide. No reliable evidence has been found that the same Limona Pearl SKU was previously officially launched in another major IQOS market.
Sep.01